Zealand Pharma and Beta Bionics to collaborate
Saturday, June 11, 2016
Zealand Pharma and Beta Bionics to collaborate on development of first-in-class dual-hormonal bionic pancreas system for treatment of people with type 1 diabetes
Financial guidance for 2016 remains unchanged.
Synergistic match of Beta Bionics' dual-hormonal, artificial, or bionic, pancreas device platform, iLet, and Zealand's liquid stable glucagon analog, ZP4207.
Expected next step under collaboration is initiation of clinical trials in H2 2016.
In future trials, the company will evaluate a multiple-dose version of its proprietary novel glucagon analog, ZP4207, with ilet.
Source : reuters.com
